74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
CytomX Therapeutics Inc
Closed
SectorHealthcare
0.6 3.45
Overview
Share price change
24h
Min
0.55
Max
0.61
Income | 13M 19M |
|---|---|
Sales | 4.7M 38M |
P/E Sector Avg | 1.673 63.778 |
EPS | 0.23 |
Profit margin | 49.552 |
Employees | 119 |
EBITDA | 14M 18M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +575.86% upside |
Next Earnings | 7 May 2025 |
|---|
Market Cap | 36K 51M |
|---|---|
Previous open | -2.85 |
Previous close | 0.6 |
News Sentiment
By Acuity
67%
33%
345 / 386 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
CytomX Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
CytomX Therapeutics Inc Forecast
Price Target
By TipRanks
575.86% upside
12 Months Forecast
Average 3.92 USD 575.86%
High 5 USD
Low 3.25 USD
Based on 4 Wall Street analysts offering 12 month price targets forCytomX Therapeutics Inc - Dist in the last 3 months.
Sentiment
By Acuity
345 / 386 Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About CytomX Therapeutics Inc
CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
